2021 MDS Highlights: Luspatercept for Very Low-Intermediate Risk, Imetelstat for R/R LR-Disease, Len in Non-TD LR Patients, Aza for TP53m, Nivo/Ipi +/- Aza, Aza & Pembro for HR-MDS, Ena for IDH2m
Login to view comments.
Click here to Login
